However, according to the current Korean guidelines for dyslipidemia, ApoB is recommended as an additional biomarker in specific clinical situations, such as diabetes and familial hypercholesterolemia, without specific cutoff values [21,22]. The gene discussed is APOB; the disease is metabolic syndrome.